Detecting prostate cancer early in men at risk is of prostate cancer can potentially improve outcomes. Prostate specific antigen (PSA) testing, however, has been shown to not be an effective method of detecting prostate cancer in the population. Similarly, guidelines currently suggest that PSA testing should be reserved to a shared decision-making process for patients and their doctors. The cost-effectiveness of PSA testing depends largely on the subsequent treatment after a positive test result and the ability to limit over-treatment and the associated negative effects for patients. This project will evaluate the PSA testing and subsequent treatments in the context of British Columbia.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.